Investments
55Portfolio Exits
14Funds
4Partners & Customers
2About 6 Dimensions Capital
6 Dimensions Capital, formed from the merger of Frontline BioVentures and WuXi Healthcare Ventures, is a healthcare-focused investment firm.
Want to inform investors similar to 6 Dimensions Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest 6 Dimensions Capital News
Nov 11, 2021
All Rights Reserved. Disclaimer: The views, opinions, forecasts, and statements made by our hosts and guests are the personal views of those respective individuals and may or may not be either endorsed or accepted by China Money Network Limited or the companies with which these individuals are employed.
6 Dimensions Capital Investments
55 Investments
6 Dimensions Capital has made 55 investments. Their latest investment was in Tongyi Medicine as part of their Series B on August 8, 2022.
6 Dimensions Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/2/2022 | Series B | Tongyi Medicine | No | 1 | ||
12/9/2021 | Series B | Halda Therapeutics | $51M | Yes | 4 | |
11/11/2021 | Series A | Ignis Therapeutics | $180M | Yes | 9 | |
11/1/2021 | Series B | |||||
10/5/2021 | Series B |
Date | 8/2/2022 | 12/9/2021 | 11/11/2021 | 11/1/2021 | 10/5/2021 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series A | Series B | Series B |
Company | Tongyi Medicine | Halda Therapeutics | Ignis Therapeutics | ||
Amount | $51M | $180M | |||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 4 | 9 |
6 Dimensions Capital Portfolio Exits
14 Portfolio Exits
6 Dimensions Capital has 14 portfolio exits. Their latest portfolio exit was GRAIL on August 18, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/18/2021 | Acquired | 36 | |||
7/16/2021 | IPO | Public | 6 | ||
7/13/2021 | IPO | Public | 4 | ||
Date | 8/18/2021 | 7/16/2021 | 7/13/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 36 | 6 | 4 |
6 Dimensions Capital Acquisitions
3 Acquisitions
6 Dimensions Capital acquired 3 companies. Their latest acquisition was Gloria Biotech on August 17, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
8/17/2018 | Corporate Majority | 2 | ||||
5/18/2017 | ||||||
5/18/2017 |
Date | 8/17/2018 | 5/18/2017 | 5/18/2017 |
|---|---|---|---|
Investment Stage | |||
Companies | |||
Valuation | |||
Total Funding | |||
Note | Corporate Majority | ||
Sources | 2 |
6 Dimensions Capital Fund History
4 Fund Histories
6 Dimensions Capital has 4 funds, including 6 Dimensions Capital.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/7/2017 | 6 Dimensions Capital | Diversified Private Equity | Closed | 1 | |
12/7/2017 | 6 Dimensions Capital RMB LP | ||||
6 Dimensions Capital Fund I | |||||
6 Dimensions Affiliates Fund |
Closing Date | 12/7/2017 | 12/7/2017 | ||
|---|---|---|---|---|
Fund | 6 Dimensions Capital | 6 Dimensions Capital RMB LP | 6 Dimensions Capital Fund I | 6 Dimensions Affiliates Fund |
Fund Type | Diversified Private Equity | |||
Status | Closed | |||
Amount | ||||
Sources | 1 |
6 Dimensions Capital Partners & Customers
2 Partners and customers
6 Dimensions Capital has 2 strategic partners and customers. 6 Dimensions Capital recently partnered with Menlo Therapeutics on April 4, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
4/23/2020 | Licensor | United States | BRIDGEWATER , N.J. , April 23 , 2020 -- Menlo Therapeutics Inc. , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology , today announced that its wholly-owned subsidiary , Foamix Pharmaceuticals Ltd. , has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited , an affiliate of Cutia Therapeutics for AMZEEQ ™ topical foam , 4 % as well as its other topical minocycline product candidates , once approved , on an exclusive basis in Greater China . | 2 | |
4/23/2020 | Licensor |
Date | 4/23/2020 | 4/23/2020 |
|---|---|---|
Type | Licensor | Licensor |
Business Partner | ||
Country | United States | |
News Snippet | BRIDGEWATER , N.J. , April 23 , 2020 -- Menlo Therapeutics Inc. , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology , today announced that its wholly-owned subsidiary , Foamix Pharmaceuticals Ltd. , has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited , an affiliate of Cutia Therapeutics for AMZEEQ ™ topical foam , 4 % as well as its other topical minocycline product candidates , once approved , on an exclusive basis in Greater China . | |
Sources | 2 |
6 Dimensions Capital Team
6 Team Members
6 Dimensions Capital has 6 team members, including current Chief Executive Officer, Leon Chen.
Name | Work History | Title | Status |
|---|---|---|---|
Leon Chen | Chief Executive Officer | Current | |
Name | Leon Chen | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.